龍津藥業(002750.SZ):上半年預虧1270萬元-1890萬元 虧損增加
格隆匯7月13日丨龍津藥業(002750.SZ)公佈2023年半年度業績預吿,報吿期歸屬於上市公司股東的淨利潤虧損1270萬元至1890萬元,扣除非經常性損益後的淨利潤虧損1600萬元至2330萬元,基本每股收益虧損0.0317元/股至0.0472元/股。
自中成藥省際聯盟集中帶量採購執行以來,醫療機構採購量不及預期,注射用燈盞花素中標價和銷售量較上年同期下降,疊加醫保支付限制等政策持續影響,且子公司工業大麻花葉本期未實現銷售,公司營業收入減少。因產能利用率較低致營業成本並未明顯下降,同時現金管理投資收益和政府補助同比減少,導致本期虧損增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.